Beruflich Dokumente
Kultur Dokumente
BLESER
1550 Southlin Drive
Kirkwood, Missouri 63122
314-966-6531
rb6f5f9c@westpost.net
Work
Experience KV Pharmaceutical Company
Vice President, Special Projects Business Development
(April, 2009 - June, 2010)
Responsibilities: Support the organization during re-organization.
Accomplishments: Led development of a team-based manufacturing strategy. Leadi
ng teams for technology transfer of manufacture of two key products to off-shore
producer, and one ANDA asset. Established and implemented strategy to divest in
ternational license portfolio.
President Pharmaceutical Division
(April, 2007 - April, 2009)
Responsibilities: Accountable for round the clock operation of manufacturing a
nd distribution facilities, quality, safety, corporate engineering, and supply c
hain support.
Accomplishments: Established operational excellence support, sales, inventory a
nd operational planning system; safety leadership team; developed a facilities m
aster plan; participated in 3 FDA inspections, resulting in entry of Consent Dec
ree.
Tyco Healthcare/Mallinckrodt, Inc. (Currently Covidien plc)
Vice President, Technology
(September, 2001 - April, 2007)
Responsibilities: Accountable for development of new active pharmaceutical ingr
edients and dosage pharmaceutical products process support of manufacturing unit
s, and pilot plant operations, with an annual budget of $50 million.
Accomplishments: Established streamlined development and technology transfer sy
stems to improve timeliness of regulatory filings and technology transfers while
improving the system against right the first time metrics; developed and implem
ented a facility plan to enable meeting of growth objectives; initiated and impl
emented a low cost manufacturing strategy with Chinese partners.
Vice President and General Manager, Operations
(December, 1997 - September, 2001)
General Manager, Operations
(February, 1995 - December, 1997)
Responsibilities: Accountable for Mallinckrodt's largest manufacturing site, wh
ich produces one-third of the Company's products, with an average operational bu
dget of $250 million and capital budget of $30 million annually.
Site statistics: Round the clock, chemical processing of active pharmaceutical
ingredients (including products regulated by the DEA); 1100 employees (475 repre
sented by the UAW); 45 acres; 20 manufacturing units; 5 laboratory buildings; 4
separate R & D units.